Key points are not available for this paper at this time.
Despite the apparent insights into stroke pathophysiology, an abundance of promising targets in preclinical development, several underpowered phase I/II clinical trials that have detected signals of effectiveness, 151617 and all large phase II/ III randomized controlled clinical trials of neuroprotectants
Dirnagl et al. (Fri,) studied this question.